I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.

Learn more about whether GitLab Inc. or Intapp, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.